Which vaccine schedule works best? new study aims to protect babies from pneumococcal disease

NCT ID NCT07591181

First seen Jun 26, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study compares two schedules (2+1 vs 3+1 doses) of a 13-valent pneumococcal vaccine in 210 healthy infants starting at 2 months old. Researchers will measure antibody levels and track side effects to find the best way to prevent pneumococcal infections.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance

13-valent pneumococcal polysaccharide conjugate vaccine (PCV13)

What this could lead to

If successful, this could help determine the most effective and safe vaccination schedule to protect infants from pneumococcal disease.

What could go wrong

This is an early-stage study with only 210 participants, so results may not apply broadly. The vaccine may not show clear differences between schedules.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for PNEUMOCOCCAL DISEASE PREVENTION are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

pneumococcal infection prevention target

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.